Shijiazhuang Pharma, Sichuan University sign drug RD agreement
Shanghai. April 25. INTERFAX-CHINA - Shijiazhuang Pharmaceutical Group Co. Ltd. (Shijiazhuang Pharma), one of China's largest drug manufacturers, has signed a drug research and development (RD) agreement worth RMB 100 million ($15.37 million) with Sichuan University, the Sichuan provincial government announced April 23.
Shijiazhuang Pharma and Sichuan University will together develop a total of around 10 drugs for the treatment of cancers, infectious diseases and viral infections, including eight Class One new drugs with either domestic or international patents already filed, the announcement said. The two parties expect the drugs to be available for sale within the next five years.
Class One new drugs are those deemed by the State Food and Drug Administration (SFDA) to have the highest level of innovation.
Sichuan University is host to a number of new drug RD platforms, involving over 200 senior research members. It has approximately 100 drugs in the RD pipeline, including 56 biological drugs, 30 chemical drugs, 10 natural drugs and 2 biological materials.
- MS